NASDAQ · RADX

Radiopharm Theranostics Limited American

$3.55 -$0.74 (-17.25%) 1D After hours
Session Pulse Overnight session 2 mentions today No new SEC filings since Mon close Full pulse →

Key Metrics

$33.82M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield
Free cash flow
Beta · 1Y 0.73
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    Offering paper hit the record (Form 424B5).

    424B5 - Radiopharm Theranostics Ltd (0001949257) (Filer)

    RECEIPT: SEC FORM 424B5, TIMESTAMPED
  • Jul 27
    An insider transaction hit the record.

    Form 4s are events, not verdicts — officers, directors, and 10% owners reporting their own trades. The forms post hours before the media writes them up.

    RECEIPT: SEC FORM 4, TIMESTAMPED
  • Jul 24
    From its Feb 2 high, the share price fell 31%.

    Peak close $5.15 on Feb 2; trough close $3.55 on Jul 24. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -31%
  • Jul 24
    The stock moved -17.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 24
  • Jul 23
    Offering paper hit the record (Form 424B5).

    424B5 - Radiopharm Theranostics Ltd (0001949257) (Filer)

    RECEIPT: SEC FORM 424B5, TIMESTAMPED
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Mar 24
    The stock moved -10.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 24

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$33.82M
Enterprise value
Shares outstanding7.9M
52-wk range$2.73 – $16.25
Avg volume · 20D189.9K
Net cash
Book value / share
ExchangeNASDAQ
About Radiopharm Theranostics Limited American
IPO dateNov 27, 2024
Employees14

Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings